In clinical practice, DecisionDx-Melanoma may, therefore, help support dermatologists with surveillance planning, referral decisions, and treatment choice for patients with early-stage melanoma. In patients with T1a/T1b melanoma, 31-GEP testing accurately stratified melanoma-specific survival (MSS) in thinner tumors and identified those patients with higher mortality risk than predicted by staging alone. In patients with T1a (n=721) and T1b (n=329) melanomas, 11.2% and 21.9%, respectively, had an increased risk (Class 1B–2B) result on 31-GEP testing. Those with Class 2B or Class 1B/2A results had significantly lower 5-year MSS than those with Class 1A results (p<0.001; Figure 2). However, increased risk 31-GEP results (Class 1B–2B) identified an additional 31% of patients with T1a and 36.7% of patients with T1b who died from melanoma compared with staging alone.